ArticlebioRxiv : the preprint server for biology2026
Concurrent Stereotactic Body Radiation Therapy and KRAS Inhibition Synergistically Improve Pre-clinical Pancreatic Cancer Treatment.
Tianyu Wang, Liang Wang, Jiaqian Xu, Youming Guo, Ling Xia, Yuting Li, Fada Guan, Boyi Gan, David S Hong, Vincent Bernard and 2 more
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Tianyu WangDepartment of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Liang WangDepartment of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jiaqian XuDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0009-0004-2094-4778 Youming GuoDepartment of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6354-6671 Ling XiaDepartment of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yuting LiDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fada GuanDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Boyi GanDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8884-6040 David S HongDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vincent BernardDepartment of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1555-608X Dadi JiangDepartment of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-0935-3908 Albert C KoongDepartment of GI Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9824-1643 Funding
Tumor hypoxia promotes acquired resistance to radiation through ferroptosis inhibitionU54CA274220 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Boyi Gan, ALBERT KOONG · 2022 to 2026
$8.4MTargeting ferroptosis in cancer therapyR01CA269646 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Boyi Gan · 2023 to 2026
$2.0MTargeting disulfidptosis in cancer: mechanisms and preclinical translationR01CA301148 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Boyi Gan · 2026 to 2026
$622kNCI NIH HHS R01 CA269646NCI NIH HHS R01 CA301148NCI NIH HHS U54 CA274220
6 · The paper itselfAbstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most challenging cancers to treat due to the dismal survival rate, poor post-treatment outcome and profound resistance to a wide range of therapies. With mutant
Identifiers
PMID42523398
PMCPMC13404893
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390